- Home
- LPTX vs SSSS Comparison
LPTX vs SSSS Comparison
Compare LPTX & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- SSSS
- Stock Information
- Founded
- LPTX 2011
- SSSS 2010
- Country
- LPTX United States
- SSSS United States
- Employees
- LPTX N/A
- SSSS N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- SSSS Finance: Consumer Services
- Sector
- LPTX Health Care
- SSSS Finance
- Exchange
- LPTX Nasdaq
- SSSS Nasdaq
- Market Cap
- LPTX 119.6M
- SSSS 138.2M
- IPO Year
- LPTX N/A
- SSSS N/A
- Fundamental
- Price
- LPTX $0.38
- SSSS $6.30
- Analyst Decision
- LPTX Buy
- SSSS Buy
- Analyst Count
- LPTX 2
- SSSS 2
- Target Price
- LPTX $8.00
- SSSS $8.00
- AVG Volume (30 Days)
- LPTX 283.3K
- SSSS 197.4K
- Earning Date
- LPTX 05-13-2025
- SSSS 05-06-2025
- Dividend Yield
- LPTX N/A
- SSSS N/A
- EPS Growth
- LPTX N/A
- SSSS N/A
- EPS
- LPTX N/A
- SSSS N/A
- Revenue
- LPTX N/A
- SSSS $3,644,430.00
- Revenue This Year
- LPTX N/A
- SSSS $6.95
- Revenue Next Year
- LPTX N/A
- SSSS N/A
- P/E Ratio
- LPTX N/A
- SSSS N/A
- Revenue Growth
- LPTX N/A
- SSSS N/A
- 52 Week Low
- LPTX $0.22
- SSSS $3.52
- 52 Week High
- LPTX $4.79
- SSSS $6.83
- Technical
- Relative Strength Index (RSI)
- LPTX 48.68
- SSSS 64.69
- Support Level
- LPTX $0.35
- SSSS $6.00
- Resistance Level
- LPTX $0.40
- SSSS $6.77
- Average True Range (ATR)
- LPTX 0.04
- SSSS 0.35
- MACD
- LPTX 0.00
- SSSS 0.04
- Stochastic Oscillator
- LPTX 53.70
- SSSS 69.08
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.